The UNBLOCK Study: Utilization of Bivalirudin On Clots in Kids
Recruitment status was Recruiting
Thrombosis is a significant medical complication in children with chronic diseases. The currently utilized treatments have many drawbacks which can lead to poor outcomes. More modern therapies are available but have not been systematically tested in children. This study will determine whether one such medication, bivalirudin is a safer and more effective alterative.
This study will monitor what effects the drug has upon the child's body and how the body processes the study drug (absorption, metabolism and elimination). The study will also evaluate the drug's effectiveness by following how long it takes to dissolve the clot. The safety issues being monitored relate to any observations of major or minor bleeding episodes after taking the drug, and/or any other side effects.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||An Open-label, Dose-finding, Pharmacokinetic, Safety and Efficacy Study of Bivalirudin in Children Between 6 Months and 18 Years of Age|
- The study will assess efficacy by re-evaluating thrombus at 48-72 hours as well as continued efficacy by re-evaluating the thrombus at ~30 days after study drug initiation. [ Time Frame: 30 days ] [ Designated as safety issue: Yes ]
- Pharmacokinetics (PK) will also be assessed by measuring plasma bivalirudin levels and correlation of the PD to the PK parameter will be performed. The study will also assess safety by evaluating for bleeding, as well as other adverse events. [ Time Frame: twice a week until drug discontinuation ] [ Designated as safety issue: Yes ]
|Study Start Date:||September 2008|
|Estimated Study Completion Date:||August 2011|
|Estimated Primary Completion Date:||July 2011 (Final data collection date for primary outcome measure)|
This will be an open-label, single-arm, dose-finding, pharmacokinetic, safety and efficacy study of bivalirudin in children 6 months to 18 years of age with deep vein thrombosis. The specific aims are as follows:
- Pharmacodynamic analysis based on the activated partial thromboplastin time (aPTT) will be performed and the best bolus dose and initial infusion dose of bivalirudin will be determined for 3 age cohorts of children.
- Pharmacokinetic analysis of bivalirudin will be determined based on bivalirudin plasma levels in the same 3 age cohorts.
- Comparison of pharmacokinetics with pharmacodynamics will be performed to determine whether the aPTT is an adequate surrogate for plasma bivalirudin levels.
- The rate of clot resolution within 48-72 hours will be determined.
- The safety of bivalirudin will be determined by assessing for major and minor bleeding and other adverse events.
A total of 30 patients will be enrolled in this study. They will be divided into 3 groups according to their age range (6 months-age to > 5, 5 to > 12 years and 12 to >18 years). The patient must have a deep vein thrombosis (clot in an artery or vein) that has been seen on an imaging test. After receiving the study drug, the subjects will then have blood tests at specific timepoints to measure how the drug is effecting the body and how the drug is acting once it is in the body. Based upon the levels of the blood tests, the dose of the study drug may be adjusted or stopped. The subject will continue on the drug until the clot is dissolved, the subject is prescribed a different anticoagulant or the physician or parents decide to remove the child off of the study. The drug will also be discontinued if any excessive bleeding or severe side effects related to the drug are observed. A follow up imaging study will be performed on all patients 48-72 hours after the drug was started. If the clot is still present at this time, another imaging study will be done at 30 days after the drug was given. The subjects will continue to have lab tests twice weekly for about 3 weeks to monitor for the effects of the drug. After completion of the study, the patient will undergo a study exit physical exam between 20-40 days after the drug was stopped.
|Contact: Christine Tam, RNemail@example.com|
|Contact: Jessica Lira, BSfirstname.lastname@example.org|
|United States, California|
|Childrens Hospital Los Angeles||Recruiting|
|Los Angeles, California, United States, 90027|
|Contact: Christine Tam, BSN 323-361-5505 email@example.com|
|Contact: Jessica Lira, BS 323-361-8875 firstname.lastname@example.org|
|Principal Investigator: Guy Young, MD|
|United States, Colorado|
|UCD Hemophilia & Thrombosis Center||Not yet recruiting|
|Aurora, Colorado, United States, 80045|
|Contact: Meghan J Calhoon 303-724-1327 email@example.com|
|Principal Investigator: Marilyn Manco-Johnson, MD|
|Principal Investigator: Neil Goldenberg, MD|
|United States, Ohio|
|Nationwide Children's Hospital||Recruiting|
|Columbus, Ohio, United States, 432005|
|Contact: Kami Perdue 614-722-6885 firstname.lastname@example.org|
|Principal Investigator: Sarah O'Brien, MD|
|United States, Pennsylvania|
|The Childrens Hospital of Philidelphia||Recruiting|
|Philadelphia, Pennsylvania, United States, 19104|
|Contact: Amanda Wade 267-426-5586 email@example.com|
|Principal Investigator: Leslie Raffini, MD|
|United States, Texas|
|University of Texas Southwestern Medical Center at Dallas||Not yet recruiting|
|Dallas, Texas, United States, 75390|
|Contact: Roberto Torres, MA 214-456-6095 Roberto.firstname.lastname@example.org|
|Principal Investigator: Janna Journeycake, MD|
|Baylor College of Medicine/Texas Children's Hospital||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: Gina Cardwell, BSN, RN 832-824-4216 email@example.com|
|Principal Investigator: Donald Yee, MD|
|Principal Investigator:||Guy A Young, MD||CHLA|